Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson's disease.
Journal
NPJ Parkinson's disease
ISSN: 2373-8057
Titre abrégé: NPJ Parkinsons Dis
Pays: United States
ID NLM: 101675390
Informations de publication
Date de publication:
30 Nov 2021
30 Nov 2021
Historique:
received:
07
04
2020
accepted:
07
06
2021
entrez:
1
12
2021
pubmed:
2
12
2021
medline:
2
12
2021
Statut:
epublish
Résumé
Levodopa-carbidopa intestinal gel (LCIG) has shown to be efficacious in motor and non-motor symptoms (NMS). Nevertheless, studies with patient Quality of Life (QoL) as a primary endpoint are scarce. To assess the effect of LCIG on Advanced Parkinson's Disease (APD) patients QoL. Secondarily, the impact on motor symptoms and NMS, emotional well-being, treatment satisfaction, and caregiver QoL, stress, disease burden, anxiety, depression, and work impairment were also investigated. In this prospective, 6-month multicenter postmarketing observational study, LCIG was administered to 59 patients with APD. Endpoints were assessed using validated scales and questionnaires. LCIG significantly improved patient QoL (PDQ-39 mean change ± standard deviation from baseline, -12.8 ± 14.6; P < 0.0001), motor symptoms (UPDRS-III in "On," -6.5 ± 11.8; P = 0.0002), NMS (NMSS, -35.7 ± 31.1; P < 0.0001), mood (Norris/Bond-Lader VAS, -6.6 ± 21.1; P = 0.0297), fatigue (PFS-16, -0.6 ± 1.0; P = 0.0003), depression (BDI-II, -5.1 ± 9.4; P = 0.0002), anxiety (BAI, -6.2 ± 9.6; P < 0.0001), and patient treatment satisfaction (SATMED-Q, 16.1 ± 16.8; P < 0.0001). There were significant correlations between the change from baseline to 6 months between PDQ-39 and UPDRS-IV, NMSS, BAI, BDI-II, AS, and PFS-16 scores, and Norris/Bond-Lader alertness/sedation factor. Caregiver anxiety also improved (Goldberg anxiety scale, -1.1 ± 1.0; P = 0.0234), but the clinical relevance of this finding is questionable. The serious adverse events reported were similar to those previously described for LCIG. In patients with APD, LCIG improves QoL, motor symptoms and NMS, emotional well-being, and satisfaction with the treatment. Improvement in patient QoL is associated with improvements in motor complications, NMS, anxiety, depression, apathy and fatigue. Improvements in patients' QoL does not correspond with improvements in caregivers' QoL or burden.
Identifiants
pubmed: 34848716
doi: 10.1038/s41531-021-00246-y
pii: 10.1038/s41531-021-00246-y
pmc: PMC8633325
doi:
Types de publication
Journal Article
Langues
eng
Pagination
108Informations de copyright
© 2021. The Author(s).
Références
Chapuis, S., Ouchchane, L., Metz, O., Gerbaud, L. & Durif, F. Impact of the motor complications of Parkinson’s disease on the quality of life. Mov. Disord. 20, 224–230 (2005).
pubmed: 15384126
doi: 10.1002/mds.20279
Olanow, C. W. et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 13, 141–149 (2014).
pubmed: 24361112
doi: 10.1016/S1474-4422(13)70293-X
Deuschl, G. et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. N. Engl. J. Med. 355, 896–908 (2006).
pubmed: 16943402
doi: 10.1056/NEJMoa060281
Katzenschlager, R. et al. Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 17, 749–759 (2018).
pubmed: 30055903
doi: 10.1016/S1474-4422(18)30239-4
Peto, V., Jenkinson, C., Fitzpatrick, R. & Greenhall, R. The development and validation of a short measure of functioning and well being for individuals with Parkinson’s disease. Qual. Life. Res. 4, 241–248 (1995).
pubmed: 7613534
doi: 10.1007/BF02260863
Martinez-Martin, P. et al. Pallidotomy and quality of life in patients with Parkinson’s disease: an early study. Mov. Disord. 15, 65–70 (2000).
pubmed: 10634243
doi: 10.1002/1531-8257(200001)15:1<65::AID-MDS1011>3.0.CO;2-Y
Nyholm, D. et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 64, 216–223 (2005).
pubmed: 15668416
doi: 10.1212/01.WNL.0000149637.70961.4C
Antonini, A. et al. Levodopa-carbidopa intestinal gel in advanced Parkinson’s: Final results of the GLORIA registry. Parkinsonism Relat. Disord. 45, 13–20 (2017).
pubmed: 29037498
doi: 10.1016/j.parkreldis.2017.09.018
Nyholm, D., Jansson, R., Willows, T. & Remahl, I. N. Long-term 24-h duodenal infusion of levodopa: outcome and dose requirements. Neurology 65, 1506–1507 (2005).
pubmed: 16275852
doi: 10.1212/01.wnl.0000183146.78892.3f
Bohlega, S. et al. Levodopa-Carbidopa Intestinal Gel Infusion Therapy in Advanced Parkinson’s Disease: Single Middle Eastern Center Experience. Eur. Neurol. 74, 227–236 (2015).
pubmed: 26618531
doi: 10.1159/000442151
Caceres-Redondo, M. T. et al. Long-term levodopa/carbidopa intestinal gel in advanced Parkinson’s disease. J. Neurol. 261, 561–569 (2014).
pubmed: 24477490
doi: 10.1007/s00415-013-7235-1
Honig, H. et al. Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov. Disord. 24, 1468–1474 (2009).
pubmed: 19425079
doi: 10.1002/mds.22596
Juhasz, A. et al. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson’s disease: An open-label study. Parkinsonism Relat. Disord. 37, 79–86 (2017).
pubmed: 28185758
doi: 10.1016/j.parkreldis.2017.02.001
Kruger, R. et al. An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson’s Disease Patients. Adv. Ther. 34, 1741–1752 (2017).
pubmed: 28631218
pmcid: 5504221
doi: 10.1007/s12325-017-0571-2
Martinez-Martin, P. et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease. Mov. Disord. 30, 510–516 (2015).
pubmed: 25382161
doi: 10.1002/mds.26067
Reddy, P. et al. Intrajejunal levodopa versus conventional therapy in Parkinson disease: motor and nonmotor effects. Clin. Neuropharmacol. 35, 205–207 (2012).
pubmed: 22821063
doi: 10.1097/WNF.0b013e3182613dea
Sensi, M. et al. Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients. J. Neural Transm. (Vienna) 121, 633–642 (2014).
doi: 10.1007/s00702-013-1153-3
Lopiano, L. et al. Motor and non-motor outcomes in patients with advanced Parkinson’s disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study. J. Neurol. 266, 2164–2176 (2019).
pubmed: 31134377
pmcid: 6687881
doi: 10.1007/s00415-019-09337-6
Ciurleo, R. et al. Assessment of Duodopa((R)) effects on quality of life of patients with advanced Parkinson’s disease and their caregivers. J. Neurol. 265, 2005–2014 (2018).
pubmed: 29951701
doi: 10.1007/s00415-018-8951-3
Antonini, A. et al. Duodenal levodopa infusion for advanced Parkinson’s disease: 12-month treatment outcome. Mov. Disord. 22, 1145–1149 (2007).
pubmed: 17661426
doi: 10.1002/mds.21500
Antonini, A. et al. Duodenal levodopa infusion improves quality of life in advanced Parkinson’s disease. Neurodegener. Dis. 5, 244–246 (2008).
pubmed: 18322402
doi: 10.1159/000113714
Chang, F. C. et al. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson’s disease. J. Clin. Neurosci. 25, 41–45 (2016).
pubmed: 26777085
doi: 10.1016/j.jocn.2015.05.059
Devos, D. & French, D. S. G. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson’s disease. Mov. Disord. 24, 993–1000 (2009).
pubmed: 19253412
doi: 10.1002/mds.22450
De Fabregues, O. et al. Long-term safety and effectiveness of levodopa-carbidopa intestinal gel infusion. Brain Behav. 7, e00758 (2017).
pubmed: 28828219
pmcid: 5561319
doi: 10.1002/brb3.758
Fasano, A., Ricciardi, L., Lena, F., Bentivoglio, A. R. & Modugno, N. Intrajejunal levodopa infusion in advanced Parkinson’s disease: long-term effects on motor and non-motor symptoms and impact on patient’s and caregiver’s quality of life. Eur. Rev. Med. Pharmacol. Sci. 16, 79–89 (2012).
pubmed: 22338551
Fernandez, H. H. et al. Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: final 12-month, open-label results. Mov. Disord. 30, 500–509 (2015).
pubmed: 25545465
doi: 10.1002/mds.26123
Foltynie, T. et al. Impact of Duodopa on Quality of Life in Advanced Parkinson’s Disease: A UK Case Series. Parkinsons Dis. 2013, 362908 (2013).
pubmed: 23476888
pmcid: 3586488
Isacson, D., Bingefors, K., Kristiansen, I. S. & Nyholm, D. Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion. Acta Neurol. Scand. 118, 379–386 (2008).
pubmed: 18547273
doi: 10.1111/j.1600-0404.2008.01049.x
Palhagen, S. E. et al. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson’s disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs. Parkinsonism Relat. Disord. 29, 17–23 (2016).
pubmed: 27318707
doi: 10.1016/j.parkreldis.2016.06.002
Puente, V. et al. Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson’s disease: impact on control of fluctuations and quality of life. Parkinsonism Relat. Disord. 16, 218–221 (2010).
pubmed: 19762271
doi: 10.1016/j.parkreldis.2009.07.015
Santos-Garcia, D., Anon, M. J., Fuster-Sanjurjo, L. & de la Fuente-Fernandez, R. Duodenal levodopa/carbidopa infusion therapy in patients with advanced Parkinson’s disease leads to improvement in caregivers’ stress and burden. Eur. J. Neurol. 19, 1261–1265 (2012).
pubmed: 22248261
doi: 10.1111/j.1468-1331.2011.03630.x
Slevin, J. T. et al. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson’s disease patients. J. Parkinsons Dis. 5, 165–174 (2015).
pubmed: 25588353
doi: 10.3233/JPD-140456
Zibetti, M. et al. Long-term duodenal levodopa infusion in Parkinson’s disease: a 3-year motor and cognitive follow-up study. J. Neurol. 260, 105–114 (2013).
pubmed: 22772358
doi: 10.1007/s00415-012-6597-0
Standaert, D. G. et al. Effect of Levodopa-carbidopa Intestinal Gel on Non-motor Symptoms in Patients with Advanced Parkinson’s Disease. Mov. Disord. Clin. Pract. 4, 829–837 (2017).
pubmed: 29242809
pmcid: 5724683
doi: 10.1002/mdc3.12526
Barrett, B., Brown, D., Mundt, M. & Brown, R. Sufficiently important difference: expanding the framework of clinical significance. Med. Decis. Mak. 25, 250–261 (2005).
doi: 10.1177/0272989X05276863
Drapier, S. et al. Quality of life in Parkinson’s disease improved by apomorphine pump: the OPTIPUMP cohort study. J. Neurol. 263, 1111–1119 (2016).
pubmed: 27060084
doi: 10.1007/s00415-016-8106-3
Dafsari, H. S. et al. Subthalamic Stimulation Improves Quality of Life of Patients Aged 61 Years or Older With Short Duration of Parkinson’s Disease. Neuromodulation 21, 532–540 (2018).
pubmed: 29266613
doi: 10.1111/ner.12740
Bellante, F., Dethy, S. & Zegers de Beyl, D. Depression, anxiety and non-motor symptoms on initiation of intrajejunal levodopa/carbidopa therapy. Acta Neurol. Belg. 116, 39–41 (2016).
pubmed: 26085378
doi: 10.1007/s13760-015-0497-x
Solla, P. et al. Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson’s disease patients treated with levodopa-carbidopa intestinal gel infusion. Parkinsonism Relat. Disord. 21, 968–971 (2015).
pubmed: 26071817
doi: 10.1016/j.parkreldis.2015.05.018
Lawrence, B. J., Gasson, N., Kane, R., Bucks, R. S. & Loftus, A. M. Activities of daily living, depression, and quality of life in Parkinson’s disease. PLoS One 9, e102294 (2014).
pubmed: 25025280
pmcid: 4099301
doi: 10.1371/journal.pone.0102294
Muller, B., Assmus, J., Herlofson, K., Larsen, J. P. & Tysnes, O. B. Importance of motor vs. non-motor symptoms for health-related quality of life in early Parkinson’s disease. Parkinsonism Relat. Disord. 19, 1027–1032 (2013).
pubmed: 23916654
doi: 10.1016/j.parkreldis.2013.07.010
Rahman, S., Griffin, H. J., Quinn, N. P. & Jahanshahi, M. Quality of life in Parkinson’s disease: the relative importance of the symptoms. Mov. Disord. 23, 1428–1434 (2008).
pubmed: 18543333
doi: 10.1002/mds.21667
Schrag, A. Quality of life and depression in Parkinson’s disease. J. Neurol. Sci. 248, 151–157 (2006).
pubmed: 16797028
doi: 10.1016/j.jns.2006.05.030
Soh, S. E., Morris, M. E. & McGinley, J. L. Determinants of health-related quality of life in Parkinson’s disease: a systematic review. Parkinsonism Relat. Disord. 17, 1–9 (2011).
pubmed: 20833572
doi: 10.1016/j.parkreldis.2010.08.012
Barone, P. et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov. Disord. 24, 1641–1649 (2009).
pubmed: 19514014
doi: 10.1002/mds.22643
Prakash, K. M., Nadkarni, N. V., Lye, W. K., Yong, M. H. & Tan, E. K. The impact of non-motor symptoms on the quality of life of Parkinson’s disease patients: a longitudinal study. Eur. J. Neurol. 23, 854–860 (2016).
pubmed: 26806538
doi: 10.1111/ene.12950
Havlikova, E. et al. Impact of fatigue on quality of life in patients with Parkinson’s disease. Eur. J. Neurol. 15, 475–480 (2008).
pubmed: 18325024
doi: 10.1111/j.1468-1331.2008.02103.x
Skorvanek, M. et al. Relationship between the non-motor items of the MDS-UPDRS and Quality of Life in patients with Parkinson’s disease. J. Neurol. Sci. 353, 87–91 (2015).
pubmed: 25918077
doi: 10.1016/j.jns.2015.04.013
Skorvanek, M. et al. Apathy in elderly nondemented patients with Parkinson’s disease: clinical determinants and relationship to quality of life. J. Geriatr. Psychiatry Neurol. 26, 237–243 (2013).
pubmed: 23970460
doi: 10.1177/0891988713500587
Hanna, K. K. & Cronin-Golomb, A. Impact of anxiety on quality of life in Parkinson’s disease. Parkinsons Dis. 2012, 640707 (2012).
pubmed: 22191074
Santos-Garcia, D. & de la Fuente-Fernandez, R. Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson’s disease. J. Neurol. Sci. 332, 136–140 (2013).
pubmed: 23890935
doi: 10.1016/j.jns.2013.07.005
Berganzo, K. et al. Motor and non-motor symptoms of Parkinson’s disease and their impact on quality of life and on different clinical subgroups. Neurologia 31, 585–591 (2016).
pubmed: 25529173
doi: 10.1016/j.nrl.2014.10.010
Ramaker, C., Marinus, J., Stiggelbout, A. M. & Van Hilten, B. J. Systematic evaluation of rating scales for impairment and disability in Parkinson’s disease. Mov. Disord. 17, 867–876 (2002).
pubmed: 12360535
doi: 10.1002/mds.10248
Shulman, L. M. et al. Disability Rating Scales in Parkinson’s Disease: Critique and Recommendations. Mov. Disord. 31, 1455–1465 (2016).
pubmed: 27193358
doi: 10.1002/mds.26649
Meara, J., Mitchelmore, E. & Hobson, P. Use of the GDS-15 geriatric depression scale as a screening instrument for depressive symptomatology in patients with Parkinson’s disease and their carers in the community. Age Ageing 28, 35–38 (1999).
pubmed: 10203202
doi: 10.1093/ageing/28.1.35
Leroi, I., McDonald, K., Pantula, H. & Harbishettar, V. Cognitive impairment in Parkinson disease: impact on quality of life, disability, and caregiver burden. J. Geriatr. Psychiatry Neurol. 25, 208–214 (2012).
pubmed: 23172765
doi: 10.1177/0891988712464823
Lawson, R. A. et al. Cognitive impairment in Parkinson’s disease: impact on quality of life of carers. Int. J. Geriatr. Psychiatry. 32, 1362–1370 (2016).
pubmed: 27925292
pmcid: 5724657
doi: 10.1002/gps.4623
Crespo-Burillo, J. A. et al. Deep brain stimulation for patients with Parkinson’s disease: Effect on caregiver burden. Neurologia 33, 154–159 (2018).
pubmed: 27443241
doi: 10.1016/j.nrl.2016.05.017
Santos-Garcia, D. & de la Fuente-Fernandez, R. Factors contributing to caregivers’ stress and burden in Parkinson’s disease. Acta Neurol. Scand. 131, 203–210 (2015).
pubmed: 25212106
doi: 10.1111/ane.12305
Hughes, A. J., Daniel, S. E., Kilford, L. & Lees, A. J. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55, 181–184 (1992).
pubmed: 1564476
pmcid: 1014720
doi: 10.1136/jnnp.55.3.181
Dubois, B. et al. Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov. Disord. 22, 2314–2324 (2007).
pubmed: 18098298
doi: 10.1002/mds.21844
Jenkinson, C., Fitzpatrick, R., Peto, V., Greenhall, R. & Hyman, N. The Parkinson’s Disease Questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age Ageing 26, 353–357 (1997).
pubmed: 9351479
doi: 10.1093/ageing/26.5.353
Goetz, C. G. et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 23, 2129–2170 (2008).
pubmed: 19025984
doi: 10.1002/mds.22340
Martinez-Martin, P. et al. International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease. Neurology 73, 1584–1591 (2009).
pubmed: 19901251
doi: 10.1212/WNL.0b013e3181c0d416
Bond, A. & Lader, M. The use of analogue scales in rating subjective feelings. Br. J. Med. Psychol. 47, 211–218 (1974).
doi: 10.1111/j.2044-8341.1974.tb02285.x
Brown, R. G., Dittner, A., Findley, L. & Wessely, S. C. The Parkinson fatigue scale. Parkinsonism Relat. Disord. 11, 49–55 (2005).
pubmed: 15619463
doi: 10.1016/j.parkreldis.2004.07.007
Starkstein, S. E. et al. Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J. Neuropsychiatry Clin. Neurosci. 4, 134–139 (1992).
pubmed: 1627973
doi: 10.1176/jnp.4.2.134
Beck, A., Steer, R. & Garbin, M. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clin. Psych. Rev. 8, 77–100 (1988).
doi: 10.1016/0272-7358(88)90050-5
Beck, A. T., Epstein, N., Brown, G. & Steer, R. A. An inventory for measuring clinical anxiety: psychometric properties. J. Consult. Clin. Psychol. 56, 893–897 (1988).
pubmed: 3204199
doi: 10.1037/0022-006X.56.6.893
Ruiz, M. A. et al. Development and validation of the “Treatment Satisfaction with Medicines Questionnaire” (SATMED-Q). Value Health 11, 913–926 (2008).
pubmed: 18494753
doi: 10.1111/j.1524-4733.2008.00323.x
Glozman, J. M., Bicheva, K. G. & Fedorova, N. V. Scale of Quality of Life of Care-Givers (SQLC). J. Neurol. 245(Suppl 1), S39–41 (1998).
pubmed: 9617723
doi: 10.1007/PL00007738
Zarit, S. H., Reever, K. E. & Bach-Peterson, J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist 20, 649–655 (1980).
pubmed: 7203086
doi: 10.1093/geront/20.6.649
Robinson, B. C. Validation of a Caregiver Strain Index. J. Gerontol. 38, 344–348 (1983).
pubmed: 6841931
doi: 10.1093/geronj/38.3.344
Goldberg, D., Bridges, K., Duncan-Jones, P. & Grayson, D. Detecting anxiety and depression in general medical settings. BMJ 297, 897–899 (1988).
pubmed: 3140969
pmcid: 1834427
doi: 10.1136/bmj.297.6653.897
Monton, C., Perez Echeverria, M. J., Campos, R., Garcia Campayo, J. & Lobo, A. [Anxiety scales and Goldberg’s depression: an efficient interview guide for the detection of psychologic distress]. Aten. Primaria 12, 345–349 (1993).
pubmed: 8218816
Tang, K., Beaton, D. E., Boonen, A., Gignac, M. A. & Bombardier, C. Measures of work disability and productivity: Rheumatoid Arthritis Specific Work Productivity Survey (WPS-RA), Workplace Activity Limitations Scale (WALS), Work Instability Scale for Rheumatoid Arthritis (RA-WIS), Work Limitations Questionnaire (WLQ), and Work Productivity and Activity Impairment Questionnaire (WPAI). Arthritis Care Res. (Hoboken) 63(Suppl 11), S337–349 (2011).
doi: 10.1002/acr.20633
Lezcano, E. et al. Improvement in quality of life in patients with advanced Parkinson’s disease following bilateral deep-brain stimulation in subthalamic nucleus. Eur. J. Neurol. 11, 451–454 (2004).
pubmed: 15257682
doi: 10.1111/j.1468-1331.2004.00804.x
Tomlinson, C. L. et al. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov. Disord. 25, 2649–2653 (2010).
pubmed: 21069833
doi: 10.1002/mds.23429